BioAffinity Technologies' 2023 acquisition Precision Pathology Laboratory Services led to more than $9.4 million in 2024 ...

Clinical and histologic characteristics and survival ... Thus, smoking not only causes lung cancer, but once NSCLC is diagnosed, the prognosis becomes worse. A biological, hormonal, and genetic ...

The increase in revenues reflects a 1,750% increase in sales of CyPath® Lung through Nov. 30, compared to the same period ...

Experts believe poor diet, more ultra-processed foods, obesity and a lack of exercise are playing a role. A long-awaited ...

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

A noteworthy case study. What's next for a premenopausal 40-year-old woman in Syria with recurrent hormone receptor-positive ...

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues ...

The FastGlioma tool could enable rapid and accurate detection of microscopic tumour infiltration, improving the success of ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

They're used to treat different cancers, such as lung, breast ... you will see M1 on a pathology report. If your tumor has metastasized, your cancer will be classified as stage III under the ...

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AILOS ...